Diagnostic Histopathology
Volume 14, Issue 9 , Pages 411-418 , September 2008

Drug-induced pathology of the upper gastrointestinal tract

References 

  1. Lewis JH. Gastrointestinal injury due to medicinal agents. Am J Gastroenterol. 1986;81:819–834
  2. Bonavina L, DeMeester TR, McChesney L, Schwizer W, Albertucci M, Bailey RT. Drug-induced esophageal strictures. Ann Surg. 1987;206:173–183
  3. Bott S, Prakash C, McCallum RW. Medication-induced esophageal injury: survey of the literature. Am J Gastroenterol. 1987;82:758–763
  4. Kikendall JW. Pill esophagitis. J Clin Gastroenterol. 1999;28:298–305
  5. Kikendall JW, Friedman AC, Oyewole MA, Fleischer D, Johnson LF. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci. 1983;28:174–182
  6. Boyce HW. Drug-induced esophageal damage: diseases of medical progress. Gastrointest Endosc. 1998;47:547–550
  7. Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005;37:740–744
  8. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol. 1999;12:1152–1157
  9. Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol. 2007;38:527–536
  10. Gencosmanoglu R, Kurtkaya-Yapicier O, Tiftikci A, Avsar E, Tozun N, Oran ES. Mid-esophageal ulceration and candidiasis-associated distal esophagitis as two distinct clinical patterns of tetracycline or doxycycline-induced esophageal injury. J Clin Gastroenterol. 2004;38:484–489
  11. Lambert JR, Newman A. Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy. Am J Gastroenterol. 1980;73:508–511
  12. Singh SP, Odze RD. Multinucleated epithelial giant cell changes in esophagitis: a clinicopathologic study of 14 cases. Am J Surg Pathol. 1998;22:93–99
  13. Dixon MF, O’Connor HJ, Axon AT, King RF, Johnston D. Reflux gastritis: distinct histopathological entity?. J Clin Pathol. 1986;39:524–530
  14. El-Zimaity HM, Genta RM, Graham DY. Histological features do not define NSAID-induced gastritis. Hum Pathol. 1996;27:1348–1354
  15. Genta RM. Differential diagnosis of reactive gastropathy. Semin Diagn Pathol. 2005;22:273–283
  16. Jacobs E, Pringot J. Gastric ulcers due to the intake of potassium chloride. Am J Dig Dis. 1973;18:289–294
  17. Sherman A, Bini EJ. Pill-induced gastric injury. Am J Gastroenterol. 1999;94:511–513
  18. Chiba T, Sato K, Endo M, et al. Upper gastrointestinal disorders induced by non-steroidal anti-inflammatory drugs. Hepatogastroenterology. 2005;52:1134–1138
  19. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000;119:521–535
  20. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med. 1998;105:3S–9S
  21. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther. 1999;13:515–519
  22. Shike M, Gillin JS, Kemeny N, Daly JM, Kurtz RC. Severe gastroduodenal ulcerations complicating hepatic artery infusion chemotherapy for metastatic colon cancer. Am J Gastroenterol. 1986;81:176–179
  23. Jewell LD, Fields AL, Murray CJ, Thomson AB. Erosive gastroduodenitis with marked epithelial atypia after hepatic arterial infusion chemotherapy. Am J Gastroenterol. 1985;80:421–424
  24. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997;112:683–689
  25. Kim SL, Hunter JG, Wo JM, Davis LP, Waring JP. NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus?. J Clin Gastroenterol. 1999;29:32–34
  26. Bjorkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med. 1998;105:17S–21S
  27. Mason JC. NSAIDs and the oesophagus. Eur J Gastroenterol Hepatol. 1999;11:369–373
  28. Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol. 2002;34:523–528
  29. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213–222
  30. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004;50:2433–2440
  31. Taha AS. Histopathological aspects of mucosal injury related to non-steroidal anti-inflammatory drugs. Ital J Gastroenterol. 1996;28(Suppl. 4):12–15
  32. Quinn CM, Bjarnason I, Price AB. Gastritis in patients on non-steroidal anti-inflammatory drugs. Histopathology. 1993;23:341–348
  33. Sung J, Russell RI, Nyeomans , et al. Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol. 2000;15(Suppl.):G58–G68
  34. Frezza M, Gorji N, Melato M. The histopathology of non-steroidal anti-inflammatory drug induced gastroduodenal damage: correlation with Helicobacter pylori, ulcers, and haemorrhagic events. J Clin Pathol. 2001;54:521–525
  35. Hawkey CJ, Naesdal J, Wilson I, et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut. 2002;51:336–343
  36. Barkin J. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Am J Med. 1998;105:22S–27S
  37. Wallace JL. How do NSAIDs cause ulcer disease?. Best Pract Res Clin Gastroenterol. 2000;14:147–159
  38. Soll A. Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity. Am J Med. 1998;105:10S–16S
  39. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–1255
  40. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528
  41. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut. 1997;41:740–747
  42. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001;64:205–213
  43. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90:1401–1406
  44. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther. 1998;12:735–740
  45. Kuipers EJ, Lee A, Klinkenberg-Knol EC, Meuwissen SG. Review article: the development of atrophic gastritis−Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther. 1995;9:331–340
  46. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018–1022
  47. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004;53:12–20
  48. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5:206–214
  49. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121:161–167
  50. McCloy RF, Arnold R, Bardhan KD, et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci. 1995;40:96S–120S
  51. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993;104:1356–1370
  52. Karnes WE, Walsh JH. The gastrin hypothesis. Implications for antisecretory drug selection. J Clin Gastroenterol. 1990;12(Suppl. 2):S7–S12
  53. Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684–690
  54. Stolte M, Bethke B, Ruhl G, Ritter M. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol. 1992;30:134–138
  55. Stolte M, Meining A, Seifert E, Alexandridis T. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract. 2000;196:9–13
  56. Choudhry U, Boyce HW, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol. 1998;110:615–621
  57. el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol. 1997;92:1858–1860
  58. Declich P, Ambrosiani L, Bellone S, et al. Fundic gland polyps under omeprazole treatment. Am J Clin Pathol. 1999;112:576–577
  59. Declich P, Ambrosiani L, Bellone S, et al. Parietal cell hyperplasia with deep cystic dilations: a lesion closely mimicking fundic gland polyps. Am J Gastroenterol. 2000;95:566–568
  60. Declich P, Tavani E, Porcellati M, Bellone S, Grassini R. Long-term omeprazole treatment and fundic gland polyps: a very authoritative proof against a link?. Am J Gastroenterol. 2001;96:1650
  61. Dickey W, Kenny BD, McConnell JB. Prevalence of fundic gland polyps in a western European population. J Clin Gastroenterol. 1996;23:73–75
  62. Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol. 2001;116:716–720
  63. Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery. 1987;101:267–272
  64. Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol. 1997;21:60–69
  65. Roy-Chaudhury P, Meisels IS, Freedman S, Steinman TI, Steer M. Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral kayexalate in sorbital therapy. Am J Kidney Dis. 1997;30:120–122
  66. Abraham SC, Bhagavan BS, Lee LA, Rashid A, Wu TT. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. Am J Surg Pathol. 2001;25:637–644
  67. Haig A, Driman DK. Iron-induced mucosal injury to the upper gastrointestinal tract. Histopathology. 2006;48:808–812
  68. Abraham SC, Park SJ, Lee JH, Mugartegui L, Wu TT. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol. 2003;16:786–795
  69. Eckstein RP, Symons P. Iron tablets cause histopathologically distinctive lesions in mucosal biopsies of the stomach and esophagus. Pathology. 1996;28:142–145
  70. Marginean EC, Bennick M, Cyczk J, Robert ME, Jain D. Gastric siderosis: patterns and significance. Am J Surg Pathol. 2006;30:514–520
  71. Abraham SC, Yardley JH, Wu TT. Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: an underrecognized entity. Am J Surg Pathol. 1999;23:1241–1247
  72. Greenson JK, Trinidad SB, Pfeil SA, et al. Gastric mucosal calcinosis. Calcified aluminum phosphate deposits secondary to aluminum-containing antacids or sucralfate therapy in organ transplant patients. Am J Surg Pathol. 1993;17:45–50
  73. Stroehlein KB, Stroehlein JR, Kahan BD, Gruber SA. Gastric mucosal calcinosis in renal transplant patients. Transplant Proc. 1999;31:2124–2126
  74. Saab S, Venkataramani A, Behling CA, Savides TJ. Gastric mucosal calcinosis in a patient with dyspepsia. J Clin Gastroenterol. 1996;22:156–164
  75. Stemmermann GN, Hayashi T. Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases. Hum Pathol. 1971;2:321–332
  76. Iacobuzio-Donahue CA, Lee EL, Abraham SC, Yardley JH, Wu TT. Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Pathol. 2001;25:1067–1073
  77. Weidner N, Smith JG, La Vanway JM. Peptic ulceration with marked epithelial atypia following hepatic arterial infusion chemotherapy. A lesion initially misinterpreted as carcinoma. Am J Surg Pathol. 1983;7:261–268
  78. Petras RE, Hart WR, Bukowski RM. Gastric epithelial atypia associated with hepatic arterial infusion chemotherapy. Its distinction from early gastric carcinoma. Cancer. 1985;56:745–750
  79. Wells JJ, Nostrant TT, Wilson JA, Gyves JW. Gastroduodenal ulcerations in patients receiving selective hepatic artery infusion chemotherapy. Am J Gastroenterol. 1985;80:425–429
  80. Brien TP, Farraye FA, Odze RD. Gastric dysplasia-like epithelial atypia associated with chemoradiotherapy for esophageal cancer: a clinicopathologic and immunohistochemical study of 15 cases. Mod Pathol. 2001;14:389–396
  81. Greco FA, Brereton HD, Kent H, Zimbler H, Merrill J, Johnson RE. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med. 1976;85:294–298
  82. Mitchell EP, Schein PS. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol. 1982;9:52–64
  83. Hruban RH, Yardley JH, Donehower RC, Boitnott JK. Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer. 1989;63:1944–1950
  84. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132
  85. Ogawa F, Mino-Kenudson M, Shimizu M, Lauwers GY. Yttrium-90 microsphere selective internal radiation-associated gastroduodenitis: a rare complication in need of recognition. Arch Pathol Lab Med, in press.

PII: S1756-2317(08)00112-6

doi: 10.1016/j.mpdhp.2008.07.001

Diagnostic Histopathology
Volume 14, Issue 9 , Pages 411-418 , September 2008

Article Tools

* Image Usage & Resolution